Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306-Reference-Cited by-同舟云学术

Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306

Published:2022-07-26 Issue:15 Volume:65 Page:10251-10284
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Szychowski Janek¹^ORCID,Papp Robert¹,Dietrich Evelyne¹,Liu Bingcan¹,Vallée Frédéric¹,Leclaire Marie-Eve¹,Fourtounis Jimmy¹,Martino Giovanni¹,Perryman Alexander L.¹,Pau Victor²^ORCID,Yin Shou Yun¹,Mader Pavel²^ORCID,Roulston Anne¹,Truchon Jean-Francois¹,Marshall C. Gary³,Diallo Mohamed¹,Duffy Nicole M.¹,Stocco Rino¹,Godbout Claude¹,Bonneau-Fortin Alexanne¹,Kryczka Rosie¹,Bhaskaran Vivek¹,Mao Daniel²,Orlicky Stephen²,Beaulieu Patrick⁴,Turcotte Pascal⁵,Kurinov Igor⁶,Sicheri Frank²⁷^ORCID,Mamane Yael¹,Gallant Michel¹,Black W. Cameron¹

Affiliation:

1. Repare Therapeutics, Inc., 7210 Frederick-Banting, Ville St-Laurent, QC H4S 2A1, Canada

2. Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON M5G 1X5, Canada

3. Repare Therapeutics, 1 Broadway, 15th Floor, Cambridge, Massachusetts 02142, United States

4. OmegaChem Inc., 480 Rue Perreault, Saint-Romuald, QC G6W 7V6, Canada

5. AdMare BioInnovations, 7171 Frederick-Banting, Montréal, QC H4S 1Z9, Canada

6. Department of Chemistry and Chemical Biology, Cornell University, NE-CAT, Argonne, Illinois 60439, United States

7. Departments of Biochemistry and Molecular Genetics, University of Toronto, Ontario M5S 1A8, Canada

Funder

Canadian Institutes of Health Research

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00552

Reference44 articles.

1. Cyclin E1 and cyclin-dependent kinase 2 are critical for initiation, but not for progression of hepatocellular carcinoma

2. Cyclin E Deregulation and Genomic Instability

3. Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases

4. CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models

5. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure-Based Drug Design of 2-Amino-[1,1′-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1-Amplified Breast Cancer;Journal of Medicinal Chemistry;2024-08-20

2. GCN2 is a determinant of the response to WEE1 kinase inhibition in small-cell lung cancer;Cell Reports;2024-08

3. Cyclin A/B RxL Macrocyclic Inhibitors to Treat Cancers with High E2F Activity;2024-08-01

4. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

5. New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives;Journal of Medicinal Chemistry;2024-07-02